16/08/2024 | Press release | Distributed by Public on 16/08/2024 11:01
|
/s/ Chaim Lebovitz
Chaim Lebovits
Chief Executive Officer |
| | | |
Shares Beneficially Owned
|
| ||||||||||||
| | |
(Includes Common Stock, Presently
Exercisable Options and Presently Exercisable Warrants) |
| |||||||||
Name of Beneficial Owner
|
| |
#
|
| |
%
|
| ||||||
Directors and Named Executive Officers in 2023 | | | | | | | | | | | | | |
Chaim Lebovits
|
| | | | 3,535,331(1) | | | | | | 4.4% | | |
Dr. Stacy Lindborg
|
| | | | 462,185(2) | | | | | | * | | |
Uri Yablonka
|
| | | | 233,633(3) | | | | | | * | | |
Alla Patlis
|
| | | | 80,246(4) | | | | | | * | | |
Ralph Kern
|
| | | | - | | | | | | * | | |
Dr. Irit Arbel
|
| | | | 383,831(5) | | | | | | * | | |
Dr. Anthony Polverino
|
| | | | 25,960(6) | | | | | | * | | |
Nir Naor
|
| | | | - | | | | | | * | | |
Dr. Jacob Frenkel
|
| | | | 206,667(7) | | | | | | * | | |
Dr. Menghisteab Bairu
|
| | | | - | | | | | | - | | |
All current directors and executive officers as a group (11 persons)
|
| | | | 5,433,595(8) | | | | | | 6.7% | | |
Name
|
| |
Age
|
| |
Position
|
|
Dr. Jacob Frenkel | | |
81
|
| | Chairperson and Director | |
Dr. Irit Arbel | | |
64
|
| | Vice-Chairperson and Director | |
Dr. Menghisteab Bairu | | |
64
|
| | Director | |
Nir Naor | | |
50
|
| | Director | |
Dr. Anthony Polverino | | |
61
|
| | Director | |
Uri Yablonka | | |
47
|
| | Director, EVP, Chief Business Officer and Secretary | |
Dr. Stacy Lindborg | | |
54
|
| | Director | |
| | |
Number of
Shares Under Amended 2014 Stock Incentive Plan (#) |
| |
Number of
Shares under Amended Global Share Plan (#) |
| ||||||
Chaim Lebovits, Chief Executive Officer
|
| | | | - | | | | | | 968,112 | | |
Dr. Ibrahim B. Dagher, Chief Medical Officer
|
| | | | 332,742 | | | | | | - | | |
Alla Patlis, Interim Chief Financial Officer
|
| | | | - | | | | | | 96,446 | | |
Dr. Hartoun Hartounian, the Chief Operating Officer
|
| | | | - | | | | | | - | | |
All current executive officers, as a group
|
| | | | 332,742 | | | | | | 1,296,191 | | |
All current directors who are not executive officers, as a group
|
| | | | 476,645 | | | | | | 377,998 | | |
Each director who is not an effective officer | | | | | | | | | | | | | |
Dr. Jacob Frenkel
|
| | | | - | | | | | | 150,000 | | |
Dr. Irit Arbel
|
| | | | - | | | | | | 227,998 | | |
Dr. Menghisteab Bairu
|
| | | | - | | | | | | - | | |
Dr. Stacy Lindborg
|
| | | | 450,685 | | | | | | - | | |
Dr. Anthony Polverino
|
| | | | 25,960 | | | | | | - | | |
Nir Naor
|
| | | | - | | | | | | - | | |
Uri Yablonka
|
| | | | - | | | | | | 231,633 | | |
Each associate of any executive officers, current directors or director
nominees |
| | | | 476,645 | | | | | | 609,631 | | |
Each other person who received or is to receive 5% of awards
|
| | | | - | | | | | | - | | |
All current employees including all current officers who are not executive officers, as a group
|
| | | | 567,503 | | | | | | 774,966 | | |
Plan category
|
| |
Number of
securities to be issued upon exercise of outstanding options, warrants and rights (a) |
| |
Weighted Average
exercise price of outstanding options, warrants and rights (b) |
| |
Number of securities
remaining available for future issuance under equity compensation plan (excluding securities referenced in column (a)) (c) |
| |||||||||
Equity compensation plans approved by security
holders: |
| | | | 1,605,783(2) | | | | | $ | 3.2671(3) | | | | | | 2,108,070(3) | | |
Equity compensation plans not approved by security holders:
|
| | | | - | | | | | | - | | | | | | - | | |
Total
|
| | | | 1,605,783 | | | | | $ | 3.2671 | | | | | | 2,108,070(1) | | |
Board Diversity Matrix (As of July 31, 2024)
|
| ||||||||||||||||||
Total Number of Directors
|
| |
7
|
| |||||||||||||||
| | |
Female
|
| |
Male
|
| |
Non-Binary
|
| |
Did Not
Disclose Gender |
| ||||||
Part I: Gender Identity | | | | | | | | | | | | | | | | | | | |
Directors
|
| | | | 2 | | | | | | 5 | | | | | | | | |
Part II: Demographic Background | | | | | | | | | | | | | | | | | | | |
African American or Black
|
| | | | | | | | | | 1 | | | | | | | | |
Alaskan Native or Native American
|
| | | | 1 | | | | | | | | | | | | | | |
Asian
|
| | | | | | | | | | | | | | | | | | |
Hispanic or Latinx
|
| | | | | | | | | | | | | | | | | | |
Native Hawaiian or Pacific Islander
|
| | | | | | | | | | | | | | | | | | |
White
|
| | | | 2 | | | | | | 4 | | | | | | | | |
Two or More Races or Ethnicities
|
| | | | 1 | | | | | | | | | | | | | | |
LGBTQ+
|
| | | | | | | | | | | | | | | | | | |
Did Not Disclose Demographic Background
|
| | | | | | | | | | | | | | | | | | |
Name
|
| |
Age
|
| |
Position
|
|
Chaim Lebovits | | |
53
|
| | Chief Executive Officer | |
Alla Patlis | | |
37
|
| | Interim Chief Financial Officer and Controller | |
Uri Yablonka | | |
47
|
| | Executive Vice President, Chief Business Officer, Secretary and Director | |
Hartoun Hartounian | | |
64
|
| | Executive Vice President and Chief Operating Officer | |
Ibrahim B. Dagher | | |
55
|
| | Executive Vice President and Chief Medial Officer | |
Name and Principal Position
|
| |
Year
|
| |
Salary
($)(1) |
| |
Bonus
($) |
| |
Stock
Awards ($)(2) |
| |
All Other
Compensation ($) |
| |
Total ($)
|
| ||||||||||||||||||
Chaim Lebovits(*),
Co-Chief Executive Officer & President |
| | | | 2023 | | | | | | 441,667 | | | | | | 250,000(3) | | | | | | 250,012 | | | | | | 187,116(4) | | | | | | 1,128,795 | | |
| | | 2022 | | | | | | 500,000 | | | | | | 250,000(5) | | | | | | 127,547 | | | | | | 240,419 | | | | | | 1,117,966 | | | ||
Ralph Kern,
Former President & Former Chief Medical Officer |
| | | | 2023 | | | | | | 29,514 | | | | | | 125,000(6) | | | | | | 671,444(7) | | | | | | 7,234(8) | | | | | | 833,192 | | |
| | | 2022 | | | | | | 500,000 | | | | | | 150,000(9) | | | | | | 106,220 | | | | | | 56,339 | | | | | | 812,559 | | | ||
Stacy Lindborg,
Co-Chief Executive Officer(10) |
| | | | 2023 | | | | | | 475,000 | | | | | | 200,000(11) | | | | | | 256,650 | | | | | | 76,075 | | | | | | 1,007,725 | | |
| | | 2022 | | | | | | 469,000 | | | | | | 164,150(12) | | | | | | 143,150 | | | | | | 75,243 | | | | | | 851,543 | | | ||
Uri Yablonka(*),
Executive Vice President, Chief Business Officer, Secretary and Director |
| | | | 2023 | | | | | | 164,780 | | | | | | - | | | | | | - | | | | | | 82,275(13) | | | | | | 247,055 | | |
Alla Patlis(*),
Interim Chief Financial Officer and Controller |
| | | | 2023 | | | | | | 98,251 | | | | | | - | | | | | | 15,864 | | | | | | 32,668(14) | | | | | | 146,783 | | |
Option Awards
|
| |
Stock Awards
|
| |
Market
Value of Shares or Units of Stock That Have Not Vested ($)(1) |
| ||||||||||||||||||||||||||||||
Name
|
| |
Number of
Securities Underlying Unexercised Options (#) Exercisable |
| |
Number of
Securities Underlying Unexercised Options (#) Unexercisable |
| |
Option
Exercise Price ($) |
| |
Option
Expiration Date |
| |
Number
of Shares or Units of Stock That Have Not Vested (#) |
| |||||||||||||||||||||
Chaim Lebovits
|
| | | | 369,619 | | | | | | - | | | | | | 2.45 | | | | | | 9/28/2025 | | | | | | - | | | | | | - | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | 7,796(2) | | | | | | 2,105 | | | ||
| | | | | | | | | | | | | | | | | | | | | | | | | | | 15,593(3) | | | | | | 4,210 | | | ||
| | | | | | | | | | | | | | | | | | | | | | | | | | | 23,389(4) | | | | | | 6,315 | | | ||
| | | | | | | | | | | | | | | | | | | | | | | | | | | 31,185(5) | | | | | | 8,420 | | | ||
Stacy Lindborg
|
| | | | 100,000 | | | | | | - | | | | | | 7.67 | | | | | | 01/06/2030 | | | | | | 26,250(6) | | | | | | 7,088 | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | 35,000(7) | | | | | | 9,450 | | | ||
Uri Yablonka
|
| | | | 33,333 | | | | | | - | | | | | | 2.70 | | | | | | 06/06/2024 | | | | | | - | | | | | | - | | |
| | | 13,333 | | | | | | - | | | | | | 0.75 | | | | | | 08/15/2024 | | | | | | - | | | | | | - | | | ||
| | | 13,333 | | | | | | - | | | | | | 0.75 | | | | | | 08/27/2025 | | | | | | - | | | | | | - | | | ||
| | | 13,333 | | | | | | - | | | | | | 0.75 | | | | | | 06/22/2026 | | | | | | - | | | | | | - | | | ||
| | | 13,333 | | | | | | - | | | | | | 0.75 | | | | | | 11/10/2027 | | | | | | - | | | | | | - | | | ||
| | | 13,333 | | | | | | - | | | | | | 0.75 | | | | | | 11/30/2028 | | | | | | - | | | | | | - | | | ||
| | | 13,333 | | | | | | - | | | | | | 0.75 | | | | | | 12/12/2029 | | | | | | - | | | | | | - | | | ||
| | | 13,333 | | | | | | - | | | | | | 0.75 | | | | | | 12/10/2031 | | | | | | - | | | | | | - | | | ||
| | | 13,333 | | | | | | - | | | | | | 0.75 | | | | | | 12/15/2031 | | | | | | - | | | | | | - | | | ||
Alla Patlis
|
| | | | 7,200 | | | | | | 2,400(8) | | | | | | 9.51 | | | | | | 10/21/2030 | | | | | | - | | | | | | - | | |
| | | 2,400 | | | | | | 7,200(9) | | | | | | 4.09 | | | | | | 09/15/2032 | | | | | | - | | | | | | - | | | ||
| | | - | | | | | | 12,000(10) | | | | | | 1.73 | | | | | | 08/01/2033 | | | | | | - | | | | | | - | | |
Year
|
| |
Summary
Compensation Table Total for PEO #1 ($)(1)(2) |
| |
Compensation
Actually Paid To PEO #1 ($)(1)(3) |
| |
Summary
Compensation Table Total for PEO #2 ($)(1)(2) |
| |
Compensation
Actually Paid To PEO #2 ($)(1)(3) |
| |
Average
Summary Compensation Table Total for Non-PEO NEOs ($)(1)(2) |
| |
Average
Compensation Actually Paid to Non-PEO NEOs ($)(1)(3) |
| |
Value of
initial fixed $100 investment based on total shareholder return (TSR) ($)(4): |
| |
Net
Loss($)(5) (in thousands) |
| ||||||||||||||||||||||||
2023
|
| | | | 1,128,795 | | | | | | 822,884 | | | | | | 1,007,725 | | | | | | 724,562 | | | | | | 409,010 | | | | | | 179,907 | | | | | | 6 | | | | | $ | (17,192) | | |
2022
|
| | | | 1,117,966 | | | | | | 897,254 | | | | | | N/A | | | | | | N/A | | | | | | 832,051 | | | | | | 631,570 | | | | | | 36 | | | | | $ | (24,277) | | |
2021
|
| | | | 1,128,349 | | | | | | 1,089,130 | | | | | | N/A | | | | | | N/A | | | | | | 837,757 | | | | | | 780,137 | | | | | | 88 | | | | | $ | (24,457) | | |
2023
|
| |
PEO #1
|
| |
PEO #2
|
| |
Non-PEO NEOs
|
| |||||||||
SCT Total Compensation
|
| | | $ | 1,128,795 | | | | | $ | 1,007,725 | | | | | $ | 409,010 | | |
Deduct amounts reported under the "Stock Awards" and "Option Awards" column of the SCT
|
| | | $ | (250,012) | | | | | $ | (256,650) | | | | | $ | (229,103) | | |
Add Fair Value of Awards Granted in 2023 Unvested as of 12/31/23
|
| | | $ | 8,420 | | | | | $ | 9,450 | | | | | $ | - | | |
Add (Deduct) Change in Fair Value of Awards Granted in Prior Years Unvested as of 12/31/23
|
| | | $ | (64,085) | | | | | $ | (35,963) | | | | | $ | - | | |
Add (Deduct) Change in Fair Value of Awards Granted in Prior Years that Vested during 2023 as of the Vesting Date
|
| | | $ | (234) | | | | | $ | - | | | | | $ | - | | |
Total Compensation Actually Paid
|
| | | $ | 822,884 | | | | | $ | 724,562 | | | | | $ | 179,907 | | |
2022
|
| |
PEO
|
| |
Non-PEO NEOs
|
| ||||||
SCT Total Compensation
|
| | | $ | 1,117,966 | | | | | $ | 832,051 | | |
Deduct amounts reported under the "Stock Awards" and "Option Awards" column of the SCT
|
| | | $ | (127,547) | | | | | $ | (124,685) | | |
Add Fair Value of Awards Granted in 2022 Unvested as of
12/31/22 |
| | | $ | 51,143 | | | | | $ | 58,126 | | |
Add (Deduct) Change in Fair Value of Awards Granted in Prior Years Unvested as of 12/31/22
|
| | | $ | (110,395) | | | | | $ | (100,580) | | |
Add (Deduct) Change in Fair Value of Awards Granted in Prior Years that Vested during 2022 as of the Vesting Date
|
| | | $ | (33,914) | | | | | $ | (33,342) | | |
Total Compensation Actually Paid
|
| | | $ | 897,253 | | | | | $ | 631,570 | | |
2021
|
| |
PEO
|
| |
Non-PEO NEOs
|
| ||||||
SCT Total Compensation
|
| | | $ | 1,128,349 | | | | | $ | 837,757 | | |
Deduct amounts reported under the "Stock Awards" and "Option Awards" column of the SCT
|
| | | $ | (110,395) | | | | | $ | (62,986) | | |
Add Fair Value of Awards Granted in 2022 Unvested as of
12/31/21 |
| | | $ | 124,736 | | | | | $ | 71,170 | | |
Add (Deduct) Change in Fair Value of Awards Granted in Prior Years Unvested as of 12/31/21
|
| | | $ | (24,792) | | | | | $ | (29,438) | | |
Add (Deduct) Change in Fair Value of Awards Granted in Prior Years that Vested during 2021 as of the Vesting Date
|
| | | $ | (28,768) | | | | | $ | (36,366) | | |
Total Compensation Actually Paid
|
| | | $ | 1,089,130 | | | | | $ | 780,137 | | |
Name
|
| |
Fees
Earned or Paid in Cash ($) |
| |
Stock
Awards ($)(1) |
| |
Option
Awards ($)(1) |
| |
Total
($) |
| ||||||||||||
Dr. Jacob Frenkel
|
| | | | - | | | | | | - | | | | | | -(2) | | | | | | - | | |
Dr. Irit Arbel
|
| | | | - | | | | | | - | | | | | | -(3) | | | | | | - | | |
Dr. June S. Almenoff(4)
|
| | | | 30,000 | | | | | | - | | | | | | - | | | | | | 30,000 | | |
Dr. Anthony Polverino(5)
|
| | | | 12,500 | | | | | | - | | | | | | - | | | | | | - | | |
Dr. Menghisteab Bairu(6)
|
| | | | - | | | | | | - | | | | | | - | | | | | | - | | |
Nir Naor(7)
|
| | | | - | | | | | | - | | | | | | - | | | | | | - | | |
Malcolm Taub(8)
|
| | | | - | | | | | | - | | | | | | - | | | | | | - | | |
| | |
December 31,
|
| |||||||||
| | |
2023
|
| |
2022
|
| ||||||
Audit Fees(1)
|
| | | $ | 100,000 | | | | | $ | 90,750 | | |
Audit-Related Fees(2)
|
| | | $ | 60,000 | | | | | $ | 60,000 | | |
Tax Fees(3)
|
| | | $ | 12,000 | | | | | $ | 12,000 | | |
Total Fees
|
| | | $ | 172,000 | | | | | $ | 162,750 | | |